Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug ...

Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

A recent study published on December 19, 2024, in the ExRNA journal highlights research from the Novosibirsk Institute of ...

Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

In early 2024, the World Health Organization predicted that by 2050 there will be more than 35 million new cancer cases ...

As robotic techniques continue to evolve, these surgical procedures hold great potential for further transforming cancer treatment and enhancing the quality of care for patients ...

Prostate Cancer UK is urging the government to update NHS guidelines so that GPs can proactively start having conversations ...

Prostate cancer waiting times could be radically cut by an 'extremely encouraging' 20 minute test, scientists have revealed.

Scientists at Heriot Watt University developed a cost-effective technique for faster, more accurate prostate cancer detection ...

Our health is our greatest asset and taking a proactive approach can prevent small issues from becoming big problems. Whether ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...